Contact A Lawyer
Near You

Contact us today for a complimentary consultation with a qualified attorney near you.

Herceptin Breast Cancer Drug

Herceptin breast cancer drug was first approved in 1998. There are very strong warnings included on the labeling of Herceptin breast cancer drug. Included on the label are warnings of cardiomyopathy and pulmonary events. The Herceptin breast cancer warning label cautions that the use of Herceptin can result in the development of ventricular dysfunction and congestive heart failure. Herceptin breast cancer patients using Herceptin along with anthracyclines and cyclophosphamides run an especially high risk of suffering cardiomyopathy.

The Herceptin breast cancer warnings include hypersensitivity reactions including anaphylaxis infusion reactions that can occur in as little as 24 hours from beginning Herceptin treatment. The fatal Herceptin breast cancer reports are what ultimately led to the increased warnings. Prior to Herceptin breast cancer drug being approved, many hoped that it would help to cure affected women, however experts did warn that Herceptin breast cancer drug might only help extend the lives of 30% of the women. It is important for every patient to completely evaluate whether or not Herceptin breast cancer drug benefits outweigh its risks prior to beginning the medication.

For more information on Herceptin breast cancer drug, please contact us.

Contact a Herceptin Recall Lawyer

More Herceptin Resources

MedLine Plus Drug Information - Guide to prescription and over-the-counter medications provided by the United States Pharmacopeia.

Herceptin.com - Official site of Herceptin anti-HER2 monoclonal antibody.